相关实验视频
Updated: Jun 13, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
快速纠正慢性高血糖和骨重塑,警告不要过度使用
Dured Dardari1, Beatrice Segurens2
1Department of Diabetology, Centre Hospitalier Sud Francilien, Corbeil Essonne 91100, France. dured.dardari@chsf.fr.
World journal of diabetes
|September 16, 2024
概括
快速纠正慢性高血糖症可能会影响骨质. 这项研究研究了葡萄糖水平的变化如何影响骨重塑阶段,为糖尿病管理期间的骨健康提供了见解.
科学领域:
- 内分泌学 在内分泌学.
- 骨生物学 骨生物学 骨生物学
- 代谢疾病 代谢疾病
背景情况:
- 众所周知,慢性高血糖症会损害骨质.
- 快速葡萄糖正常化对骨重塑的影响尚不清楚.
研究的目的:
- 为了研究慢性高血糖快速纠正对骨重塑的影响.
- 探索葡萄糖水平与骨重塑的特定阶段之间的关系.
主要方法:
- 文献综述侧重于骨重塑过程.
- 对研究的分析,这些研究将葡萄糖水平与骨质量标志物相关联.
主要成果:
- 骨重塑是一个复杂的过程,受葡萄糖平衡的影响.
- 快速的葡萄糖转移可能会对骨结构完整性带来独特的挑战.
结论:
- 了解高血糖纠正期间骨重塑的动态对于患者护理至关重要.
- 需要进一步的研究来阐明所涉及的精确机制.
相关概念视频
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Insulin: Dosing Regimen and Adverse Effects
157
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147

